Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1

Although cure rates for childhood acute lymphoblastic leukemia (ALL) have increased dramatically over recent years through the integration of risk stratification into treatment protocols [1 –3], failure of remission-inducing therapy is associated with only a 30% 10-year survival rate [4] and relapsed ALL remains the most common cause of cancer-related death in children [5–7]. There is a need for new therapeutic approaches with minimal toxicities for higher-risk leukemias.

Source: Experimental Hematology - April 12, 2018 Category: Hematology Authors: Victoria J. Weston, Wenbin Wei, Tatjana Stankovic, Pamela Kearns Source Type: research